REGENXBIO shares fell 25% in the premarket as the US FDA suspended the company's clinical trial of gene therapy for Hunter syndrome.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.